Clinical Trial

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

Study acronym: MEMENTO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-11; most recent amendment 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-07-09
Trial Details
NCT Number NCT06687876
Lead Sponsor Amsterdam UMC, location VUmc
Collaborators: Cancer Center Amsterdam Research Foundation
Conditions Oesophageal Adenocarcinoma, Tumor Microenvironment
Enrollment 14 participants
Start Date 2025-03-09
Primary Completion 2026-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-10